A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
-
Enrollment
This study is not currently enrolling. -
Research Area
Cancer Research -
Principal Investigator
Robert Holloway -
Sponsor
GOG Partners & KaryoPharm Therapeutics